Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

医学 乌斯特基努马 银屑病 安慰剂 银屑病面积及严重程度指数 临床终点 内科学 加药 随机化 体表面积 斑块性银屑病 随机对照试验 不利影响 临床试验 皮肤病科 阿达木单抗 疾病 病理 替代医学
作者
Kristian Reich,Kim Papp,Andrew Blauvelt,Richard Langley,April W. Armstrong,Richard B. Warren,Kenneth B. Gordon,Joseph F. Merola,Yukari Okubo,Cynthia Madden,Maggie Haitian Wang,Christopher L. Cioffi,Veerle Vanvoorden,Mark Lebwohl
出处
期刊:The Lancet [Elsevier BV]
卷期号:397 (10273): 487-498 被引量:215
标识
DOI:10.1016/s0140-6736(21)00125-2
摘要

Background There is an unmet need for a treatment for psoriasis that results in complete skin clearance with a reliably quick response. Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. We aimed to compare the efficacy and safety of bimekizumab with placebo and ustekinumab in patients with moderate to severe plaque psoriasis over 52 weeks. Methods BE VIVID was a multicentre, randomised, double-blind, active comparator and placebo controlled phase 3 trial done across 105 sites (clinics, hospitals, research units, and private practices) in 11 countries in Asia, Australia, Europe, and North America. Adults aged 18 years or older with moderate to severe plaque psoriasis (Psoriasis Area and Severity Index [PASI] score ≥12, ≥10% body surface area affected by psoriasis, and Investigator's Global Assessment [IGA] score ≥3 on a five point scale) were included. Randomisation was stratified by geographical region and previous exposure to biologics; patients, investigators, and sponsors were masked to treatment assignment. Patients were randomly assigned (4:2:1) using an interactive response technology to bimekizumab 320 mg every 4 weeks, ustekinumab 45 mg or 90 mg (baseline weight-dependent dosing) at weeks 0 and 4, then every 12 weeks, or placebo every 4 weeks. At week 16, patients receiving placebo switched to bimekizumab 320 mg every 4 weeks. All study treatments were administered as two subcutaneous injections. Coprimary endpoints were the proportion of patients with 90% improvement in the PASI (PASI90) and the proportion of patients with an IGA response of clear or almost clear (score 0 or 1) at week 16 (non-responder imputation). Efficacy analyses included the intention-to-treat population; safety analysis included patients who received at least one dose of study treatment. This trial was registered at ClinicalTrials.gov, NCT03370133 (completed). Findings Between Dec 6, 2017, and Dec 13, 2019, 735 patients were screened and 567 were enrolled and randomly assigned (bimekizumab 320 mg every 4 weeks n=321, ustekinumab 45 mg or 90 mg every 12 weeks n=163, placebo n=83). At week 16, 273 (85%) of 321 patients in the bimekizumab group had PASI90 versus 81 (50%) of 163 in the ustekinumab group (risk difference 35 [95% CI 27–43]; p<0·0001) and four (5%) of 83 in the placebo group (risk difference 80 [74–86]; p<0·0001). At week 16, 270 (84%) patients in the bimekizumab group had an IGA response versus 87 (53%) in the ustekinumab group (risk difference 30 [95% CI 22–39]; p<0·0001) and four (5%) in the placebo group (risk difference 79 [73–85]; p<0·0001). Over 52 weeks, serious treatment-emergent adverse events were reported in 24 (6%) of 395 patients in the bimekizumab group (including those who switched from placebo at week 16) and 13 (8%) of 163 in the ustekinumab group. Interpretation Bimekizumab was more efficacious than ustekinumab and placebo in the treatment of moderate to severe plaque psoriasis. The bimekizumab safety profile was consistent with that observed in previous studies. Funding UCB Pharma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Newky发布了新的文献求助10
1秒前
3秒前
3秒前
王路飞完成签到,获得积分10
4秒前
7秒前
mmm发布了新的文献求助10
8秒前
boltos发布了新的文献求助10
10秒前
ASA完成签到,获得积分10
10秒前
abin发布了新的文献求助10
11秒前
Newky完成签到,获得积分10
11秒前
卿君完成签到,获得积分10
15秒前
15秒前
Jasper应助乔佳怡采纳,获得10
17秒前
Akim应助hwezhu采纳,获得10
17秒前
18秒前
alpv完成签到,获得积分10
18秒前
19秒前
南冥发布了新的文献求助10
22秒前
22秒前
23秒前
迷路的绿藻头完成签到 ,获得积分10
23秒前
量子星尘发布了新的文献求助10
24秒前
哈哈完成签到,获得积分10
24秒前
A阿澍发布了新的文献求助10
25秒前
abin完成签到,获得积分10
25秒前
27秒前
27秒前
27秒前
hwezhu发布了新的文献求助10
28秒前
30秒前
jyy应助科研通管家采纳,获得10
32秒前
czh应助科研通管家采纳,获得20
32秒前
烟花应助科研通管家采纳,获得10
33秒前
充电宝应助科研通管家采纳,获得10
33秒前
小马甲应助科研通管家采纳,获得10
33秒前
33秒前
今后应助科研通管家采纳,获得10
33秒前
33秒前
无花果应助科研通管家采纳,获得10
33秒前
skbkbe发布了新的文献求助10
33秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989263
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253814
捐赠科研通 3270066
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136